Extract from the Clinical Evaluation Report for Pralatrexate

Patients with renal impairment have been identified as a special population of interest and the sponsor submitted the protocol for a study in patients with advanced cancer and mild, moderate, and severe renal impairment (Study PDX-019). This study is in the earliest stages of enrolment and no data had been generated at the time of submission. ................
................